Response to letter regarding article, "Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry".

نویسندگان

  • Benjamin Hibbert
  • Andrea MacDougall
  • Melissa Blondeau
  • Edward R O'Brien
  • Derek Y F So
  • Marino Labinaz
  • Alexander Dick
  • Christopher Glover
  • Michael Froeschl
  • Jean-Francois Marquis
  • George A Wells
  • Michel R Le May
چکیده

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Letter by Johnson et al regarding article, "Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry".

BACKGROUND Data from randomized trials has demonstrated the superiority of bivalirudin to glycoprotein IIb/IIIa inhibitors plus heparin in patients undergoing primary percutaneous coronary intervention. Real-world performance of bivalirudin in primary percutaneous coronary intervention and the benefit of bivalirudin over heparin remain unknown in an era of routine dual antiplatelet therapy. M...

متن کامل

The Rise and Fall of Anticoagulation with Bivalirudin During Percutaneous Coronary Interventions: A Review Article

Bivalirudin is a direct thrombin inhibitor used during percutaneous coronary intervention (PCI). Treatment with bivalirudin compared to heparin plus glycoprotein IIb/IIIa inhibitors (GPI) reduced bleeding complications, but resulted in higher rates of ischemic events, including acute stent thrombosis in ST segment elevation myocardial infarction (STEMI) patients. Thus, it may be considered a re...

متن کامل

Antithrombins: Pathophysiology and Pharmacology

Mortality rates for acute ST-segment–elevation myocardial infarction (STEMI) have improved dramatically over the past 3 decades: effective reperfusion therapy has been the cornerstone of this improvement, with recent trends showing growth in primary percutaneous coronary intervention (PCI). Although mortality rates for routine risk STEMI patients are now ≈5%, process and procedure challenges re...

متن کامل

Is heparin an acceptable anticoagulant when glycoprotein IIb/IIIa inhibitors are not used?

T he relationship between bleeding complications and increased mortality after percutaneous coronary intervention (PCI) has been well documented. Bivalirudin is superior to heparin and glycoprotein (GP) IIb/IIIa inhibitors, mainly due to the lower risk of bleeding but comparable rates of ischemic complications (1–3). Three trials presented at the 2014 American College of Cardiology Scientific S...

متن کامل

Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database.

BACKGROUND Randomized trials show improved outcomes among acute coronary syndrome patients treated with bivalirudin. The objective of this analysis was to compare clinical and economic outcomes in ST-elevation myocardial infarction (STEMI) patients encountered in routine clinical practice undergoing primary percutaneous coronary intervention (PPCI), treated with bivalirudin or heparin+GP IIb/II...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Circulation. Cardiovascular interventions

دوره 6 2  شماره 

صفحات  -

تاریخ انتشار 2013